SION (Sionna Therapeutics) Stock Based Compensation: $16.53 Mil (TTM As of Mar. 2026)


SION Sionna Therapeutics Inc SION
12 GF Score
Price $43.99
! 3 Warning Signs
View Full Analysis

What is Sionna Therapeutics Stock Based Compensation?

Sionna Therapeutics SION +5.64% 12 Stock Based Compensation is $16.53 Mil as of Mar. 2026. GuruFocus rates SION with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

Sionna Therapeutics's Stock Based Compensation for the three months ended in Mar. 2026 was $6.55 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $16.53 Mil.

Sionna Therapeutics Stock Based Compensation Related Terms

Sionna Therapeutics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Sionna Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sionna Therapeutics Stock Based Compensation Chart

Sionna Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
1.69 2.26 3.71 12.07

Sionna Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 2.09 2.84 3.31 3.83 6.55
SION
12GF Score
Sionna Therapeutics Inc SION
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sionna Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $16.53 Mil.

What does a Stock Based Compensation of $16.53 Mil mean?
Sionna Therapeutics (SION) has a Stock Based Compensation of $16.53 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Sionna Therapeutics and its competitors.
Is Sionna Therapeutics' Stock Based Compensation too high?
Sionna Therapeutics' current Stock Based Compensation is $16.53 Mil. Overall, Sionna Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sionna Therapeutics' Stock Based Compensation compare to TYRA and RAPP?
Sionna Therapeutics' Stock Based Compensation of $16.53 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Sionna Therapeutics and its competitors. Sionna Therapeutics's current Stock Based Compensation is $16.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sionna Therapeutics stock overvalued right now?
Sionna Therapeutics (SION) has a current Stock Based Compensation of $16.53 Mil. The current Stock Based Compensation is $16.53 Mil. Sionna Therapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Sionna Therapeutics (SION), the current Stock Based Compensation is $16.53 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sionna Therapeutics Business Description

Address 21 Hickory Drive, Suite 500, Waltham, MA, USA, 02451
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
12GF Score

Get the complete analysis for SION

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$43.99
Price